Ziccum AB (publ)
ZICC.ST
Stockholm Stock Exchange0.25
SEK
- -
- -
Ziccum AB (publ)
ZICC.ST
(Stockholm Stock Exchange)
Recent
price
0.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ziccum AB (publ) develops and commercializes LaminarPace, a patented drying technology for biopharmaceuticals and vaccines that uses mass transfer rather than heat transfer to dry liquid biologics into thermostable dry powders. The company’s core products and services include the LaminarPace drying system, which enables formulation and manufacture of particle-engineered dry powder biopharmaceuticals suitable for novel administration routes such as inhalation. It targets vaccines, mRNA/LNP vaccines, viral vector vaccines, and subunit (adjuvanted) vaccine platforms for the global pharmaceutical industry. Ziccum offers its technology primarily through licensing and technology transfer agreements to vaccine and biologics developers and manufacturers. The business model focuses on partnering with pharmaceutical companies to scale and industrialize the LaminarPace drying equipment for manufacturing, supported by a strong patent portfolio and continuous technology development. Ziccum operates internationally with a headquarters in Sweden and emphasizes reducing production losses, energy use, and operational costs by gentler manufacturing processes for delicate biologics. In the last two years, Ziccum signed a long-term agreement with GMP equipment specialist RFR Solutions to industrialize and scale out the LaminarPace drying equipment. It also entered an evaluation agreement with US clinical-stage genetic medicines company ReCode Therapeutics to test LaminarPace for dry powder mRNA therapeutic modalities. The company filed three patent applications in 2023 to strengthen its IP portfolio. However, in January 2025, Ziccum’s board resolved to file for bankruptcy due to insufficient financing despite a rights issue completed in late 2024 and declined financing requests from its main investor. The company halted trading on the First North exchange and ceased operations after failing to secure continued funding to support technology and business development based on the LaminarPace platform. Founded in 2013 and headquartered in Lund, Sweden, Ziccum emerged as a spin-off from ISAB and has focused on next-generation vaccine and biologics formulation technologies. Its key strategic focus areas included licensing its patented LaminarPace technology, advancing powder characteristics for expanded drug delivery routes, and industrial scaling with contract manufacturing partners. The recent bankruptcy filing marks a significant operational and financial setback for the company despite its innovative drying technology platform and active partnership efforts. Thus, Ziccum AB (publ) specializes in next-generation biopharmaceutical drying using its LaminarPace mass transfer platform, targeting global vaccine and biologics manufacturers, but it entered bankruptcy proceedings in early 2025 due to financing challenges.